314.98—Postmarketing reports.
(a)
Except as provided in paragraph (b) of this section, each applicant having an approved abbreviated new drug application under § 314.94 that is effective shall comply with the requirements of § 314.80 regarding the reporting and recordkeeping of adverse drug experiences.
(b)
Each applicant shall submit one copy of each report required under § 314.80 to the Central Document Room, Center for Drug Evaluation and Research, Food and Drug Administration, 5901-B Ammendale Rd., Beltsville, MD 20705-1266.
(c)
Each applicant shall make the reports required under § 314.81 and section 505(k) of the act for each of its approved abbreviated applications.